**Supplementary Appendix**

**Table S1**: Baseline characteristics of participants who were followed during different types of periods. The subgroups are not mutually exclusive, as the same woman may undergo different types of periods.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Subgroup1****UntreatedGestation(N=149)\*** | **Subgroup2****UntreatedPostpartum(N=92)** | **Subgroup3****On treatmentGestation(N=49)** | **Subgroup4****On treatmentPostpartum(N=36)** | **Subgroup5****After** **withdrawal(N=29)** |
| **N** | **% or****Median(range)** | **N** | **% or****Median(range)** | **N** | **% or****Median(range)** | **N** | **% or****Median(range)** | **N** | **% or****Median(range)** |
| **Age (years)** | 149 | 32(18,49) | 92 | 33(22,51) | 49 | 31(23,40) | 36 | 31(23,40) | 29 | 31(24,40) |
| **Race** |  |  |  |  |  |  |  |  |  |  |
|  White | 12 | 8% | 10 | 11% | 1 | 2% | 1 | 3% | 0 | 0% |
|  Black | 27 | 18% | 19 | 21% | 3 | 6% | 2 | 6% | 1 | 3% |
|  Asian | 109 | 73% | 62 | 67% | 43 | 88% | 31 | 86% | 28 | 97% |
|  Other | 1 | 1% | 1 | 1% | 2 | 4% | 2 | 6% | 0 | 0% |
| **Genotype**  |  |  |  |  |  |  |  |  |  |  |
|  A | 22 | 17% | 17 | 22% | 1 | 2% | 0 | 0% | 0 | 0% |
|  B | 49 | 38% | 32 | 41% | 16 | 33% | 12 | 34% | 11 | 38% |
|  C | 45 | 35% | 20 | 25% | 27 | 56% | 20 | 57% | 16 | 55% |
|  D | 6 | 5% | 7 | 9% | 2 | 4% | 1 | 3% | 1 | 3% |
|  Other | 7 | 5% | 3 | 4% | 2 | 4% | 2 | 6% | 1 | 3% |
| **Born in North America** | 26 | 17% | 17 | 18% | 4 | 8% | 3 | 8% | 3 | 10% |
| **HBeAg** |  |  |  |  |  |  |  |  |  |  |
|  Positive | 56 | 39% | 19 | 21% | 40 | 87% | 30 | 86% | 26 | 96% |
|  Negative | 87 | 61% | 71 | 79% | 6 | 13% | 5 | 14% | 1 | 4% |
| **ALT (U/L)** |  |  |  |  |  |  |  |  |  |  |
|  Overall | 144 | 22(5,513) | 88 | 21(6,69) | 49 | 25(9,513) | 36 | 25(9,513) | 29 | 20(12,135) |
|  HBeAg+ | 55 | 25(12,513) | 18 | 25(12,44) | 40 | 25(9,513) | 30 | 25(9,513) | 26 | 20(12,135) |
|  HBeAg- | 84 | 21(6,69) | 68 | 21(6,69) | 6 | 21(11,70) | 5 | 25(11,70) | 1 | 17 |
| **HBV DNA (IU/mL)** |  |  |  |  |  |  |  |
|  Overall | 147 | 1208(BLQ,ALQ) | 92 | 362(BLQ,4.1×109) | 49 | 7.3×106(BLQ,ALQ) | 36 | 9.5×106(BLQ,ALQ) | 29 | 1.2×108(BLQ,ALQ) |
|  HBeAg+ | 56 | 1.3×108(31,ALQ) | 19 | 4.1×107(31, 4.1×109) | 40 | 5.2×107(BLQ,ALQ) | 30 | 4.3×107(BLQ,ALQ) | 26 | 1.3×108(BLQ,ALQ) |
|  HBeAg- | 86 | 350(BLQ,1.3×106) | 71 | 210(BLQ, 4.2×105) | 6 | 465(BLQ,2.0×105) | 5 | 258(BLQ,2.0×105) | 1 | 672 |
| **APRI**  |  |  |  |  |  |  |  |  |  |  |
|  Overall | 124 | 0.3(0.1,4.4) | 77 | 0.3(0.1,0.8) | 42 | 0.3(0.2,4.4 | 32 | 0.3(0.2,4.4) | 26 | 0.3(0.2,0.8) |
|  HBeAg+ | 47 | 0.3(0.1,4.4) | 15 | 0.2(0.1,0.7) | 35 | 0.3(0.2,4.4) | 27 | 0.3(0.2,4.4) | 24 | 0.3(0.2,0.8) |
|  HBeAg- | 74 | 0.3(0.1,0.8) | 61 | 0.3(0.1,0.8) | 5 | 0.5(0.2,0.6) | 4 | 0.5(0.2,0.6) | 1 | 0.4 |
| **Phenotype** |  |  |  |  |  |  |  |  |  |  |
|  IT, HBeAg+ | 15 | 11% | 3 | 3% | 15 | 33% | 11 | 31% | 13 | 48% |
|  IA, HBeAg+ | 28 | 20% | 7 | 8% | 16 | 35% | 12 | 34% | 11 | 41% |
|  IA, HBeAg- | 6 | 4% | 4 | 5% | 0 | 0% | 0 | 0% | 0 | 0% |
|  IC, HBeAg- | 36 | 26% | 30 | 35% | 2 | 4% | 1 | 3% | 1 | 4% |
|  Indeterminant | 53 | 38% | 42 | 49% | 13 | 28% | 11 | 31% | 2 | 7% |

\*All but one participant in subgroup 1 were untreated at enrollment. For that participant, antiviral therapy initiated 6 days before enrollment. As this participant was an adjudicated spontaneous flare based on clinical notes, we included her in the denominator for calculating spontaneous flare rates.

**Table S2:** Baseline characteristics among women who experienced a spontaneous flare (N=9)vs. women who did not experience any flare during the follow-up (N=136).

|  |  |  |  |
| --- | --- | --- | --- |
|   | **Spontaneous flare** | **No Flare\*** | **p-value&** |
|   | **Number** | **Proportion ormedian (range)** | **Number** | **Proportion ormedian (range)** |   |
| **Age (years)** | 9 | 31(27,37) | 136 | 32(18,51) | 0.649 |
| **Race** |   |   |   |   | 0.377 |
| White | 1 | 11% | 11 | 8% |   |
| Black | 0 | 0% | 27 | 20% |   |
| Asian | 8 | 89% | 97 | 71% |   |
| Other | 0 | 0% | 1 | 1% |   |
| **Born in North America** | 1 | 11% | 25 | 18% | >0.9 |
| **Genotype**  |   |   |   |   | 0.497 |
|  A | 0 | 0% | 22 | 19% |   |
|  B | 4 | 44% | 45 | 39% |   |
|  C | 4 | 44% | 37 | 32% |   |
|  D | 1 | 11% | 6 | 5% |   |
|  Other (E & F) | 0 | 0% | 6 | 5% |   |
| **HBeAg** |   |   |   |   |   |
|  Positive | 6 | 67% | 45 | 35% | 0.074 |
|  Negative | 3 | 33% | 85 | 65% |   |
| **HBV DNA (IU/mL)** |   |   |   |   |   |
|  overall | 9 | 7.3×106(672,4.1×109) | 134 | 750(BLQ,ALQ) | 0.005 |
|  among HBeAg+ | 6 | 9.4×107(9.6×104, 4.1×109) | 45 | 1.2×108(31,ALQ) | ─ |
|  among HBeAg- | 3 | 3.8×103(672,2.0×105) | 84 | 328(BLQ,1.3×106) | ─ |
| **ALT (U/L)** |   |   |   |   |   |
|  overall | 9 | 38(15,513) | 131 | 21(5,69) | 0.113 |
|  among HBeAg+ | 6 | 87(15,513) | 44 | 25(12,52) | ─ |
|  among HBeAg- | 3 | 17(17,39) | 82 | 21(6,69) | ─ |
| **APRI** |   |   |   |   |   |
|  overall | 6 | 0.3(0.2,4.4) | 114 | 0.3(0.1,0.8) | 0.459 |
|  among HBeAg+ | 4 | 0.2(0.2,4.4) | 38 | 0.3(0.1,0.7) | ─ |
|  among HBeAg- | 2 | 0.4(0.4,0.4) | 73 | 0.3(0.1,0.8) | ─ |
| **Phenotype** |   |   |   |   | 0.345 |
|  IT, HBeAg positive | 2 | 22 | 11 | 9 |   |
|  IA, HBeAg positive | 3 | 33 | 22 | 18 |   |
|  IA, HBeAg negative | 0 | 0 | 6 | 5 |   |
|  IC, HBeAg negative | 1 | 11 | 36 | 29 |   |
|  Indeterminant | 3 | 33 | 50 | 40 |   |

**&** P-value is not provided when n is too small.

\*Women with non-viable outcomes or treatment-related flares were exclude.

**Figure S1. ALT -Flares: Spontaneous reactivation**

|  |  |
| --- | --- |
|  | **Subject 1**Prior to conception: ALT 54 U/L and DNA of 1.97×108 IU/ mL (8.3 log10 IU/mL). **Flare:****Onset:** First trimester (10 weeks)**Grade\***: moderate**Duration:** 24 weeks**Treatment initiated:** no**HBeAg loss:** no**HBV DNA:**  decrease (> 10 fold) with flare |
|  | **Subject 2****Flare: 1st flare****Onset:** Second trimester (27 weeks)**Grade**: mild**Duration:** unknown**Treatment**: yes**HBeAg loss:** no**HBV DNA:** decrease (> 10 fold) with flare |
|  | **Subject 3****Flare:****Onset:** Third trimester (28 weeks)**Grade\***: moderate**Duration:** 39 weeks**Treatment initiated:** yes**HBV DNA:** increase (> 10 fold) with flare |
|  | **Subject 4****Flare:****Onset:** Third trimester (30 weeks)**Grade\***: moderate**Duration:** >48 weeks**Treatment initiated:** yes**HBeAg loss:** transient**HBV DNA change with flare:** unknown |
|  | **Subject 5****Flare:****Onset:** Third trimester (39 weeks)**Grade\*\***: moderate**Duration:** 15 weeks**Treatment initiated:** yes**HBV DNA:** increase (> 10 fold) with flare |
|  | **Subject 6****Flare:****Onset:** Post-partum (6 weeks)**Grade**: mild**Duration:** >36 weeks**Treatment initiated:** no**HBV DNA:** increase (> 10 fold) with flare |
|  | **Subject 7****Flare:****Onset:** Post-partum (10 weeks)**Grade\*\***: moderate**Duration:** >37 weeks**Treatment initiated:** no**HBeAg loss:** no**HBV DNA:** no change with flare (<10 fold) |
|  | **Subject 8****Flare:****Onset:** Post-partum (11 weeks)**Grade**: mild**Duration: >**25 weeks**Treatment initiated:** no**HBeAg loss:** no**HBV DNA:** decrease (> 10 fold) with flare |
|  | **Subject 9****Flare:** **Onset:** Post-partum (42 weeks)**Grade:** mild**Duration:** >5 weeks**Treatment initiated:** yes**HBeAg loss:** no**HBV DNA:** no change with flare (<10 fold) |

* The blue lines represent ALT (in ULN, such that each unit represents 20 U/L). ALT values above 10 ULN (i.e., 200 U/L) were plotted at 10 ULN, with actual values (in U/L) labeled on the figure in blue.
* The red lines represent HBV DNA (in log10 IU/mL). For example, a value of 3 means 103 IU/mL and a value of 7 means 107 IU/mL. Each unit increase in log10 IU/mL corresponds to 10-fold increase in the original scale (IU/mL).
* The grey area means the woman was receiving antiviral treatment.
* \*confirmed by HBRN Adjudication Committee to be related to pregnancy
* \*\*unknown or not yet confirmed by HBRN Adjudication Committee to be related to pregnancy

**Figure S2. ALT Flares: on antiviral therapy**

|  |  |
| --- | --- |
|  | **Subject 1****Flare:****Onset:** Second trimester (17 weeks)**Grade:** mild**Duration:** unknown**HBeAg loss:** unknown**HBV DNA:** unknown |
|  | **Subject 2****Flare:****Onset:** Post-partum (13 weeks)**Grade**: mild**Duration: >**31 weeks**HBeAg loss:** no**HBV DNA:** no change with flare (<10 fold) |
|  | **Subject 3****Flare:****Onset:** Post-partum (7 weeks)**Grade\***: moderate**Duration:** 12 weeks**HBeAg loss:** no**HBV DNA:** decrease (> 10 fold) with flare |

* The blue lines represent ALT (in ULN, such that each unit represents 20 U/L). ALT values above 10 ULN (i.e., 200 U/L) were plotted at 10 ULN, with actual values (in U/L) labeled on the figure in blue.
* The red lines represent HBV DNA (in log10 IU/mL). For example, a value of 3 means 103 IU/mL and a value of 7 means 107 IU/mL. Each unit increase in log10 IU/mL corresponds to 10-fold increase in the original scale (IU/mL).
* The grey area means the woman was receiving antiviral treatment.
* \*confirmed by HBRN Adjudication Committee to be related to pregnancy

**Figure S3. ALT Flares: after withdrawal of therapy**

|  |  |
| --- | --- |
|  | **Subject 1****Flare:****Onset:** 11 weeks after discontinuation of therapy**Grade**: mild**Duration: >**26 weeks**Retreatment**: no**HBeAg loss:** no**HBV DNA:** no change with flare (<10 fold) |
|  | **Subject 2****Flare:****Onset:** 14 weeks after discontinuation of therapy**Grade**: mild**Duration: >**12 weeks**Retreatment**: no**HBeAg loss:** no**HBV DNA:** increase (>10 fold) with flare  |
|  | **Subject 3****Flare:****Onset:** 14 weeks after discontinuation of therapy**Grade**: mild**Duration:** 16 weeks**Retreatment**: no**HBeAg loss:** no**HBV DNA:** increase (>10 fold) with flare  |
|  | **Subject 4****Flare:****Onset:** 7 weeks after discontinuation of therapy**Grade**: mild**Duration:** >25 weeks**Retreatment**: no**HBeAg loss:** no**HBV DNA:** decrease (>10 fold) with flare |
|  | **Subject 5****Flare: 2nd flare****Onset:** 12 weeks after discontinuation of therapy**Grade\***: moderate**Duration:** >19 weeks**Retreatment**: no**HBeAg loss:** Yes**HBV DNA:** no change with flare (<10 fold) |

* The blue lines represent ALT (in ULN, such that each unit represents 20 U/L). ALT values above 10 ULN (i.e., 200 U/L) were plotted at 10 ULN, with actual values (in U/L) labeled on the figure in blue.
* The red lines represent HBV DNA (in log10 IU/mL). For example, a value of 3 means 103 IU/mL and a value of 7 means 107 IU/mL. Each unit increase in log10 IU/mL corresponds to 10-fold increase in the original scale (IU/mL).
* The grey area means the woman was receiving antiviral treatment.
* \*confirmed by HBRN Adjudication Committee to be related to withdrawal of therapy